Redeye endorses BioInvent's divestment of its royalty and milestone rights to mezagitamab. This provides BioInvent with income and prolongs its financial runway further into 2026.
ANNONS
Redeye endorses BioInvent's divestment of its royalty and milestone rights to mezagitamab. This provides BioInvent with income and prolongs its financial runway further into 2026.